--- title: "Director At Liquidia Sells $1.99M Of Stock" type: "News" locale: "en" url: "https://longbridge.com/en/news/291952457.md" description: "Stephen M Bloch, a director at Liquidia (NASDAQ:LQDA), sold 25,000 shares worth approximately $1.99 million on July 6, according to an SEC Form 4 filing. At the time of the transaction, Liquidia's stock was trading at $79.03, up 1.75%. The company is a biopharmaceutical firm focused on pulmonary hypertension treatments using its proprietary PRINT technology." datetime: "2026-07-07T15:00:21.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/291952457.md) - [en](https://longbridge.com/en/news/291952457.md) - [zh-HK](https://longbridge.com/zh-HK/news/291952457.md) generator: "portal-rs" --- # Director At Liquidia Sells $1.99M Of Stock **Stephen M Bloch**, Director at **Liquidia** (NASDAQ:LQDA), executed a substantial insider sell on July 6, according to an SEC filing. **What Happened:** Bloch's recent Form 4 filing with the U.S. Securities and Exchange Commission on Monday unveiled the sale of 25,000 shares of **Liquidia**. The total transaction value is $1,986,694. Tracking the Tuesday's morning session, **Liquidia** shares are trading at $79.03, showing a up of 1.75%. ### Get to Know Liquidia Better Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil. ### A Deep Dive into Liquidia's Financials **Positive Revenue Trend:** Examining Liquidia's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of **4158.49%** as of 31 March, 2026, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector. **Holistic Profitability Examination:** - Gross Margin: With a high gross margin of 91.08%, the company demonstrates effective cost control and strong profitability relative to its peers. - Earnings per Share (EPS): With an EPS below industry norms, Liquidia exhibits below-average bottom-line performance with a current EPS of 0.6. **Debt Management:** Liquidia's debt-to-equity ratio stands notably higher than the industry average, reaching **1.7**. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage. **Analyzing Market Valuation:** - Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 465.94 suggests caution, as the stock may be overvalued in the eyes of investors. - Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 24.76 as compared to the industry average, the stock might be considered overvalued based on sales performance. - EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): With an impressive EV/EBITDA ratio of 130.24, Liquidia demonstrates exemplary market valuation, surpassing industry averages. **Market Capitalization Perspectives:** The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale. ### Why Insider Transactions Are Important Considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors. In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company’s equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction. Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise. Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors. ### The Insider's Guide to Important Transaction Codes When it comes to transactions, investors tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A **P** in Box 3 denotes a purchase, while **S** indicates a sale. Transaction code **C** signals the conversion of an option, and transaction code **A** denotes a grant, award, or other acquisition of securities from the company. Check Out The Full List Of Liquidia's Insider Trades. *This article was generated by Benzinga's automated content engine and reviewed by an editor.* ### Related Stocks - [LQDA.US](https://longbridge.com/en/quote/LQDA.US.md) ## Related News & Research - [Liquidia director Katherine Rielly-Gauvin reports common share sale worth $4.08 million](https://longbridge.com/en/news/296650554.md) - [Rajeev Saggar Sells 50,000 Shares of Liquidia (NASDAQ:LQDA) Stock](https://longbridge.com/en/news/296477852.md) - [Liquidia (LQDA) Turns Profitable On YUTREPIA Growth, Is The Upside Already Priced In?](https://longbridge.com/en/news/296513877.md) - [Renaissance Technologies LLC Sells 198,753 Shares of Liquidia Corporation $LQDA](https://longbridge.com/en/news/296325354.md) - [Liquidia Chief Medical Officer Rajeev Saggar disposes of USD 5.97 million in common shares](https://longbridge.com/en/news/296406687.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**